RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes

Trends in Endocrinology and Metabolism

Volumn 11, Issue 9, 2000, Pages 368-375

  Schmidt, Ann Marie ^a   Stern, David M ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL PERMEABILITY; DIABETIC ANGIOPATHY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN; INFLAMMATION; RECEPTORS, IMMUNOLOGIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033779614     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00311-8     Document Type: Review

References (72)

1. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
2. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues
3. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
4. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor
5. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage
6. Advanced glycosylation in diabetes and aging
7. Glucose and diabetic vascular disease
8. Accumulation of Maillard products in skin collagen in diabetes and aging
9. Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging
10. Carboxymethyllysine protein adduct is a major immunological epitope in proteins modified with AGEs of the Maillard reaction
11. Carboxymethyllysine is a dominant AGE antigen in tissue proteins
12. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions
13. Immunohistochemical detection of AGEs in diabetic tissues using monoclonal antibody to pyrraline
14. Role of oxidative stress in development of complications in diabetes
15. Immunological presence of AGEs in atherosclerotic lesions of euglycemic rabbits
16. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation endproducts at sites of inflammation
17. Beta-2-microglobulin modified with AGEs is a major component of hemodialysis-associated amyloidosis
18. Nonenzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide
19. Pentosidine formation in skin correlates with severity of complications in individuals with longstanding IDDM
20. Increased collagen-linked pentosidine levels and AGEs in early diabetic nephropathy
21. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity
22. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface
23. Cloning and expression of RAGE: A cell surface receptor for advanced glycosylation end products of proteins
24. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
25. The V-domain of receptor for advanced glycation end-products (RAGE) mediates binding of AGEs: A novel target for therapy of diabetes
26. N-(carboxymethyl)lysine modifications of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression
27. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/ calgranulin polypeptides
28. Macrophages adhere to glucose-modified basement membrane via their scavenger receptors
29. Galectin-2 as a high affinity binding protein for AGE: A new member of the AGE-receptor complex
30. The dark side of glucose (News and Views)
31. RAGE is a cellular binding site for amphoterin: Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system
32. RAGE mediates the interaction of AGE-beta-2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis
33. Tissue distribution of the receptor for advanced glycation end-products (RAGE): Expression in smooth muscle, cardiac myocytes, and neural tissue in-addition to vasculature
34. Expression of RAGE in peripheral occlusive vascular disease
35. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
36. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation endproducts
37. Sp1 binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells
38. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1): A potential mechanism for the accelerated vasculopathy of diabetes
39. Global endothelial activation induced by AGEs and its relevance for inflammation
40. Advanced glycation endproducts (AGEs) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications
41. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant property
42. Regulation of mononuclear phagocyte migration by cell surface binding proteins for advanced glycosylation endproducts
43. Advanced glycation endproducts activate the expression of monocyte and smooth muscle cell chemoattractants by vascular smooth muscle cells
44. Enhanced cellular oxidant stress by the interaction of AGEs with their receptors/binding proteins
45. Activation of RAGE triggers a MAP kinase pathway regulated by oxidant stress
46. Receptor for advanced glycation endproducts (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways
47. The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
48. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
49. Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy
50. Prospective study of microalbuminuria as predictor of mortality in NIDDM
51. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in noninsulin-dependent diabetes mellitus
52. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin-induced diabetes
53. The receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to AGEs in the intravascular space
54. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble RAGE blocks hyperpermeability
55. Increased atherosclerosis in streptozotocin-induced diabetic mice
56. Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects
57. Diabetes and cardiovascular disease: The Framingham Study
58. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
59. Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE)
60. The S100 family of EF-hand calcium-binding proteins: Functions and pathology
61. The S100 protein family: History, function, and expression
62. Prevalence of periodontal disease in insulin-dependent diabetes mellitus
63. Type 2 diabetes mellitus and periodontal disease
64. Periodontal disease. The sixth complication of diabetes mellitus
65. Comparison of neutrophil chemotactic response in diabetic patients with mild and severe periodontal disease
66. Neutrophil chemotaxis in individuals with advanced periodontal disease and a genetic predisposition to diabetes mellitus
67. Diabetes increases collagenase activity in extracts of rat gingiva and skin
68. Tetracycline administration increases protein (presumably procollagen) synthesis and secretion in periodontal ligament fibroblasts of streptozotocin-induced diabetic rats
69. 2 shows stable interindividual differences
70. Monocytic TNF-α secretion patterns in IDDM patients with periodontal diseases
71. Murine model of accelerated periodontal disease in diabetes
72. Blockade of RAGE suppresses periodontitis-associated alveolar bone loss in diabetic mice